TXMD


TherapeuticsMD (TXMD) Stock Has Triple-Digit Upside From Here, Says Analyst

TherapeuticsMD (TXMD) investors are keeping an eye on the pace of commercialization efforts for Imvexxy, Annovera, and Bijuva. That will prove critical for …

Analyst Sees Compelling Opportunity in Therapeutics MD (TXMD) Stock As Women’s Meds Grow in Popularity

Cantor’s analyst Louise Chen assumes coverage on pharmaceutical company TherapeuticsMD (TXMD) with an Overweight rating and price target of $27, showing an upside …

This Analyst Explains Why TherapeuticsMD (TXMD) Stock Should End 2018 on a High Note

Last Thursday, TherapeuticsMD (TXMD) announced that it has entered into discussions with the FDA regarding the proposed label for TX-001, the company’s experimental …

Oppenheimer Shares Key Takeaways from Meeting with TherapeuticsMD (TXMD) Management; Reiterates Outperform Rating on the Stock

TherapeuticsMD (TXMD) is on its way to transitioning to a commercial-stage company. Recall, Imvexxy is approved for the treatment of moderate-to-severe vaginal pain …

Oppenheimer Reiterates Bullish Stance on TherapeuticsMD (TXMD) Following Business Update

TherapeuticsMD (NYSE:TXMD) CEO Robert Finizio and Co-founder Brian Bernick presented today at the 13th Annual Wells Fargo Securities Healthcare Conference in Boston. The management team provided a business …

Key FDA Decisions Could Power These 3 Biopharma Stocks

Today, we list 3 biopharma companies that have FDA events approaching along with positive analyst sentiment. In other words, analysts expect these companies’ …

TherapeuticsMD (TXMD): The Next 12-18 Months Could be a Period of Positive Stock Performance, Says Cantor

TherapeuticsMD (NASDAQ:TXMD) announced Friday that the FDA has approved its vaginal contraceptive system known as ANNOVERA. ANNOVERA is the first long-acting prescription birth control …

Oppenheimer Bullish on TherapeuticsMD (TXMD) Following Expansion of Leading Portfolio

Oppenheimer analyst Jay Olson is out with a new research note on shares of TherapeuticsMD (NYSE:TXMD), following the news that the drug maker has entered into …

Oppenheimer Sees 125% Upside for TherapeuticsMD (TXMD) Stock; Here’s Why

Oppenheimer analyst Jay Olson is out today with a bullish research note on shares of TherapeuticsMD (NASDAQ:TXMD), after the drug maker reported second-quarter results and …

Cantor Pounds the Table on TherapeuticsMD (TXMD) Stock

Cantor analyst William Tanner is out pounding the table on shares of TherapeuticsMD (NASDAQ:TXMD), reiterating an Overweight rating and price target of $26, which implies an …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts